Nongenetic mechanisms of resistance or adaptation to ibrutinib have been described in mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL) and involve CD79b overexpression or compensatory PI3K activation (14–17). Here, CD79B is linked to diffuse large B-cell lymphoma.